ascopubs.org

Impact of gene expression signatures of immune infiltration on response to sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin in high-risk non ...

A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract ...
Targeted Oncology

Convergence in GU Cancers: Precision Meets Payload

When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...
ascopubs.org

The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over ...

The prognosis for patients with bladder cancer with recurrence after pathologic complete response or pathologic downstaging after radical cystectomy: EUMC RC cohort study. This is an ASCO Meeting ...
MedPage Today

First-Line Bladder Cancer Trial Makes the Case for HER2 Screening

BERLIN -- A Chinese trial that screened advanced urothelial cancer patients for HER2-expression demonstrated a large survival benefit with a novel chemotherapy-free combination in the first-line ...
Cure Today

Aidixi Combination Therapy Improves Survival in Urothelial Carcinoma

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.